Drawing for ISM RESEARCH GROUP

USPTO serial 86749257

ISM RESEARCH GROUP

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MARSH, BRANDON N
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ISM RESEARCH GROUP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael Shariff

MICHAEL SHARIFF Inventa Capital Plc40900 Woodward Ave Ste 111Bloomfield Hills, MI 48304-5116UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005A pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals, namely, for treatment of AIDS, infectious diseases; a pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on humans, namely, for AIDS, infectious diseases, a pharmaceutical composition featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable, the pharmaceutical composition for treating AIDS, infectious diseasesACTIVE—
044medical services featuring a pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of stable isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 % and administering a first of the stable isotopes at least prior to and after surgical removal of a solid tumor to prevent possible metastases and occurrence of secondary effects and to prevent metastasizing followed by administering a second of the stable isotopes to transform a cancer cell phenotype into a normal cell, wherein the pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable; medical testing for diagnostics purposes for diagnosis of pathology in biological objects featuring comparative analysis of light and heavy isotopes concentrations of vital chemical elements, wherein concentrations of light and heavy isotopes are compared to the ones corresponding to a natural distribution of isotopes for a given chemical elementACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 22, 2018MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 22, 2018ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 22, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 20, 2018EX3GSOU EXTENSION 3 GRANTED—
Mar 20, 2018EXT3SOU EXTENSION 3 FILED—
Mar 20, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 22, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 20, 2017EX2GSOU EXTENSION 2 GRANTED—
Sep 20, 2017EXT2SOU EXTENSION 2 FILED—
Sep 20, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 18, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 17, 2017EX1GSOU EXTENSION 1 GRANTED—
Jul 14, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 20, 2017NREVNOTICE OF REVIVAL - E-MAILED—
Jun 19, 2017TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Jun 19, 2017PETGPETITION TO REVIVE-GRANTED—
Jun 19, 2017PROATEAS PETITION TO REVIVE RECEIVED—
Apr 24, 2017MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 24, 2017ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 20, 2017EXT1SOU EXTENSION 1 FILED—
Sep 20, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 26, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 26, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 6, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 16, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 11, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 11, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 11, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 30, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 30, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 30, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 18, 2015DOCKASSIGNED TO EXAMINER—
Sep 10, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 10, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance